Mytesi
Antiretroviral Therapy, Diarrhea
Treatment
3 FDA approvals
0 Active Studies for Mytesi
Treatment for
Antiretroviral Therapy
What is Mytesi
Crofelemer
The Generic name of this drug
Treatment Summary
Crofelemer, also known as Fulyzaq, is a drug made from the bark of the Croton lechleri tree found in the Amazon rainforest. It is used to treat symptoms of non-infectious diarrhea in adults with HIV/AIDS who are taking antiretroviral therapy.
Fulyzaq
is the brand name
Mytesi Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fulyzaq
Crofelemer
2012
2
Approved as Treatment by the FDA
Crofelemer, commonly known as Fulyzaq, is approved by the FDA for 3 uses like Noninfectious diarrhea and Antiretroviral Therapy .
Noninfectious diarrhea
Antiretroviral Therapy
Diarrhea
Effectiveness
How Mytesi Affects Patients
Crofelemer helps to reduce diarrhea by blocking a protein that helps the body lose too much water. Unlike other drugs, it does not make diarrhea worse when treatment ends, does not disrupt the body's natural movements, and is not absorbed into the bloodstream, so it has fewer chances of causing side effects or interacting with other drugs.
How Mytesi works in the body
Crofelemer works by blocking two channels in the intestinal cells, CFTR and CaCC. This prevents fluid from leaving the body too quickly, which can help reduce diarrhea. It does this by blocking chloride, a type of salt, from passing out of the cells.
When to interrupt dosage
The suggested measure of Mytesi is contingent upon the established condition. The amount of dosage changes, depending upon the delivery approach detailed in the table beneath.
Condition
Dosage
Administration
Antiretroviral Therapy
125.0 mg,
Oral, , Tablet, coated, Tablet, coated - Oral
Diarrhea
125.0 mg,
Oral, , Tablet, coated, Tablet, coated - Oral
Warnings
Common Mytesi Drug Interactions
Drug Name
Risk Level
Description
Mytesi Toxicity & Overdose Risk
Common side effects of this drug include coughing, bloating, upper respiratory infection, bronchitis, and jaundice.
Mytesi Novel Uses: Which Conditions Have a Clinical Trial Featuring Mytesi?
An active clinical trial is presently exploring the use of Mytesi to manage Diarrhea.
Condition
Clinical Trials
Trial Phases
Antiretroviral Therapy
0 Actively Recruiting
Diarrhea
0 Actively Recruiting
Patient Q&A Section about mytesi
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
When was Mytesi FDA approved?
"announced that the FDA had approved Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Mytesi FDA Approval History Mytesi (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. Mytesi (crofelemer) was first approved as Fulyzaq in December 2012. In October 2016, Napo Pharmaceuticals, Inc. announced that the FDA had approved Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy."
Answered by AI
How long does it take Mytesi to work?
"When will my symptoms start to improve? After 4 weeks of treatment with Mytesi, most patients see a reduction in the frequency of watery bowel movements. When taken daily, patients usually continue to see improvement in their symptoms for up to 20 weeks."
Answered by AI
How much does Mytesi cost?
"The drug crofelemer has a retail price of about $2,859.23."
Answered by AI